Consider it a success case or a bright point of discovery in the search for cancer inhibitors. An international team of researchers has identified a new compound to potentially disarm AKR1C3, an upregulated enzyme found in prostate, breast and other cancers, using AI-based drug screening and brilliant X-ray light at MAX IV. Is this study a diamond in the rough or a glimpse of more to come in biomedical research using artificial intelligence?
MAX IV is making significant societal contributions in terms of record-high scientific productivity. In 2023, the number of publications increased by 51% compared to the previous year, and the number of unique users increased by 31%. Moreover, the number of proposals submitted in the most recent Open Call was higher than ever.
After successfully bringing the first 16 funded beamlines into operation, we now look into the future. In collaboration with the Wallenberg Initiative Materials Science for Sustainability (WISE), funded by the Knut and Alice Wallenberg Foundation and together with the scientific community, MAX IV will develop the conceptual designs for three potential new materials science beamlines.